Houston biotech cos. begin clinical trials for cancer, Covid-19 treatments

Both Iterion and Moleculin are moving their drug candidates through the regulatory pipeline.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news

Related Links:

At the Journal of the Advanced Practitioner in Oncology annual conference, experts discussed the best innovations in cancer care during the coronavirus pandemic to date.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Conclusion: Anxiety and sleep quality levels were found comparable to pre-pandemic reports, and the pandemic was not observed to have additional negative impact on cancer patients. Also, universal basal anxiety and sleep disorder that accompany cancer or active treatment were observed in our study. The accurate effects of the pandemic can be analyzed in further studies using repeated data obtained from the same patient group.Chemotherapy
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research
Conclusion: ABCD-10 showed acceptable overall performance, but revealed mortality underestimation and was inferior to the performance of SCORTEN. In consistence with SCORTEN, ABCD-10 was a better model when using values collected at day 3 of hospitalization relative to day 1.Dermatology
Source: Dermatology - Category: Dermatology Source Type: research
Changes in body composition over time can be identified on total-body dual-energ...Read more on AuntMinnie.comRelated Reading: Body composition analysis predicts mortality in spinal metastases Body composition on CT lung screening can spot at-risk patients Can body composition metrics foretell COVID-19 patient outcomes? Chest CT assesses COPD mortality risk AI body analysis finds lung cancer survival risk factors
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Chris EdwardsThe main weapons against COVID-19 are the vaccines developed by Moderna and BioNTech after a decade of their research into mRNA technologies. That research was supported by more than $3 billion of private angel investment and venture capital.Democrats and Republicans both support medical research funding, and Republicans tout the Trump administration ’s Operation Warp Speed. But governments were not the key to mRNA development. Instead, we can thank the leaders and scientists at Moderna and BioNTech and the suppliers of private capital to them, as I discusshere andhere.TheWall Street Journal &r...
Source: Cato-at-liberty - Category: American Health Authors: Source Type: blogs
Transl Res. 2021 Dec 3:S1931-5244(21)00284-X. doi: 10.1016/j.trsl.2021.12.001. Online ahead of print.ABSTRACTPatients with cancers have been severely affected by the COVID-19 pandemic. This is highlighted by the adverse outcomes in cancer patients with COVID-19 as well as by the impact of the COVID-19 pandemic on cancer care. Patients with cancer constitute a heterogeneous population that exhibits distinct mechanisms of immune dysfunction, associated with distinct systemic features of hot (T-cell-inflamed/infiltrated) and cold (Non-T-cell-inflamed/infiltrated) tumors. The former show hyper immune activated cells and a high...
Source: Translational Research : the journal of laboratory and clinical medicine - Category: Laboratory Medicine Authors: Source Type: research
Curr Res Pharmacol Drug Discov. 2021;2:100062. doi: 10.1016/j.crphar.2021.100062. Epub 2021 Oct 5.ABSTRACTCOVID-19 is an infectious disease that affects the respiratory system and is caused by the novel coronavirus SARS-CoV-2. It was first reported in Wuhan, China, on December 31, 2019, and has affected the entire world. This pandemic has caused serious health, economic and social problems. In this situation, the only solution to combat COVID-19 is to accelerate the development of antiviral drugs and vaccines to mitigate the virus and develop better antiviral methods and excellent diagnostic and prevention techniques. With...
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research
This study aimed to determine the impact of pulmonary complications on death after surgery both before and during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.METHODS: This was a patient-level, comparative analysis of two, international prospective cohort studies: one before the pandemic (January-October 2019) and the second during the SARS-CoV-2 pandemic (local emergence of COVID-19 up to 19 April 2020). Both included patients undergoing elective resection of an intra-abdominal cancer with curative intent across five surgical oncology disciplines. Patient selection and rates of 30-day postoper...
Source: The British Journal of Surgery - Category: Surgery Authors: Source Type: research
CONCLUSION: HFRT seems to be a good treatment with an acceptable prolonged disease control. In older patients fit for radical treatments, a 55 Gy in 20 fractions regimen can be proposed as a valid alternative to the standard fractionated RT, but there are a multitude of hypofractionated regimens, ranging from single fraction, quad shot, and 1-, 2-, 3-, 4-, and 5-week schedules that all may be appropriate. The correct regimen for a patient depends on many factors, and it represents the result of a more specific and complex decision.PMID:34868976 | PMC:PMC8633531 | DOI:10.3389/fonc.2021.761393
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research
Front Immunol. 2021 Aug 19;12:601080. doi: 10.3389/fimmu.2021.601080. eCollection 2021.ABSTRACTCOVID-19, the disease caused by SARS-CoV-2 infection, can assume a highly variable disease course, ranging from asymptomatic infection, which constitutes the majority of cases, to severe respiratory failure. This implies a diverse host immune response to SARS-CoV-2. However, the immunological underpinnings underlying these divergent disease courses remain elusive. We therefore set out to longitudinally characterize immune signatures of convalescent COVID-19 patients stratified according to their disease severity. Our unique conva...
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research
More News: American Health | Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | COVID-19 | Health Management